Orion Portfolio Solutions LLC reduced its holdings in shares of DaVita Inc. (NYSE:DVA – Free Report) by 14.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,302 shares of the company’s stock after selling 898 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in DaVita were worth $869,000 at the end of the most recent reporting period.
A number of other institutional investors have also made changes to their positions in DVA. Transcendent Capital Group LLC acquired a new stake in DaVita in the 3rd quarter valued at $25,000. Blue Trust Inc. increased its position in shares of DaVita by 58.6% in the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after acquiring an additional 78 shares during the last quarter. Family Firm Inc. bought a new stake in DaVita during the second quarter worth about $43,000. Quarry LP bought a new position in DaVita in the third quarter valued at approximately $60,000. Finally, Point72 Hong Kong Ltd acquired a new position in shares of DaVita during the 2nd quarter worth approximately $68,000. Institutional investors own 90.12% of the company’s stock.
Analyst Ratings Changes
Several equities research analysts have recently commented on DVA shares. Barclays increased their price objective on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Truist Financial lifted their price objective on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, DaVita presently has an average rating of “Hold” and an average target price of $161.80.
DaVita Trading Down 0.8 %
DVA stock opened at $152.73 on Monday. The stock has a market cap of $12.52 billion, a price-to-earnings ratio of 16.48, a price-to-earnings-growth ratio of 0.86 and a beta of 0.90. The company has a fifty day moving average price of $157.94 and a two-hundred day moving average price of $150.86. DaVita Inc. has a one year low of $103.40 and a one year high of $169.51. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33.
DaVita (NYSE:DVA – Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The company had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The firm’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter last year, the company posted $2.85 EPS. Equities analysts anticipate that DaVita Inc. will post 9.71 EPS for the current year.
DaVita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
See Also
- Five stocks we like better than DaVita
- How to Start Investing in Real Estate
- Dave & Buster’s: Is It Time to Make Another Play on This Stock?
- EV Stocks and How to Profit from Them
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Short Selling: How to Short a Stock
- Texas Instruments: The Old-School Tech Titan Still Delivering
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.